Catalent Pharma Solutions, Inc. - FORM 10-K - EX-32.2 - CERTIFICATION OF THE CFO PURSUANT TO 18 U.S.C. SECTION 1350 - September 17, 2010

Attached files

file filename
10-K - FORM 10-K - Catalent Pharma Solutions, Inc.d10k.htm
EX-10.3 - FORM OF SEVERANCE AGREEMENT - Catalent Pharma Solutions, Inc.dex103.htm
EX-31.2 - CERTIFICATION OF THE CFO PURSUANT TO RULE 13A-14(A) OR RULE 15D-14(A) - Catalent Pharma Solutions, Inc.dex312.htm
EX-10.8 - MANAGEMENT EQUITY SUBSCRIPTION AGREEMENT (ARTHUR J. HIGGINS) - Catalent Pharma Solutions, Inc.dex108.htm
EX-31.1 - CERTIFICATION OF THE CEO PURSUANT TO RULE 13A-14(A) OR RULE 15D-14(A) - Catalent Pharma Solutions, Inc.dex311.htm
EX-32.1 - CERTIFICATION OF THE CEO PURSUANT TO 18 U.S.C. SECTION 1350 - Catalent Pharma Solutions, Inc.dex321.htm
EX-21.1 - LIST OF SUBSIDIARIES - Catalent Pharma Solutions, Inc.dex211.htm
EX-10.6 - OFFER LETTER, DATED JULY 24, 2009 (SCOTT HOULTON) - Catalent Pharma Solutions, Inc.dex106.htm
EX-10.4 - OFFER LETTER, DATED MAY 4, 2009 (STEPHEN LEONARD) - Catalent Pharma Solutions, Inc.dex104.htm
EX-10.7 - MANAGEMENT EQUITY SUBSCRIPTION AGREEMENT (MELVIN D. BOOTH) - Catalent Pharma Solutions, Inc.dex107.htm
EX-10.5 - OFFER LETTER, DATED DECEMBER 16, 2009 (KURT NIELSEN) - Catalent Pharma Solutions, Inc.dex105.htm
EX-10.18 - FORM OF NONQUALIFIED STOCK OPTION AGREEMENT - Catalent Pharma Solutions, Inc.dex1018.htm
EX-10.16 - AMENDMENT NO. 1 TO THE 2007 PTS HOLDING CORP. STOCK INCENTIVE PLAN - Catalent Pharma Solutions, Inc.dex1016.htm
EX-12.1 - STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES - Catalent Pharma Solutions, Inc.dex121.htm

Exhibit 32.2

Certification of the Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350,

As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report of Catalent Pharma Solutions, Inc. (the “Company”) on Form 10-K for the year ended June 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Matthew M. Walsh, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: September 17, 2010

 

/s/ Matthew M. Walsh

Matthew M. Walsh

Senior Vice President and

Chief Financial Officer

Catalent Pharma Solutions, Inc. Reports